GV and Alexandria have taken part in a $191m round to launch Maze Therapeutics with scientific co-founders from multiple universities such as Harvard and Stanford.
US-based biotechnology developer Maze Therapeutics launched yesterday with $191m in funding provided by a consortium featuring GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet. Alexandria Venture Investments, the investment arm of life science real estate trust Alexandria Real Estate Equities, also participated in the round co-led by Third Rock Ventures and Arch…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Talking Tech Transfer interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
